Respiratory Medicine and Research最新文献

{"title":"Anti-synthetase syndrome: A focus on interstitial lung disease as a diagnostic criteria","authors":"Jessica A. Peterson ,&nbsp;Caroline Cook ,&nbsp;Hanzhi Gao ,&nbsp;Raju Reddy ,&nbsp;Bruno Hochhegger ,&nbsp;Diana Gomez-Manjarres ,&nbsp;Faye Pais","doi":"10.1016/j.resmer.2025.101190","DOIUrl":"10.1016/j.resmer.2025.101190","url":null,"abstract":"<div><h3>Background</h3><div>Anti-synthetase syndrome (ASyS) is an autoimmune disorder with clinical manifestations that often include interstitial lung disease (ILD), myositis, and arthritis. Although it shares features with other idiopathic inflammatory myopathies, ILD is more prevalent and often more severe in this syndrome. The aim of this study was to compare Connors and Solomon diagnostic criteria for ASyS and investigated whether the presence of no additional symptoms, one additional symptom, or two or more symptoms, in addition to ILD and relevant antibodies, would indicate a worse prognosis.</div></div><div><h3>Methods</h3><div>This retrospective single-center study examined patients who were previously diagnosed with ASyS based on Connors or Solomon criteria and were further categorized using the 273rd ENMC International workshop criteria and post-hoc. The patients were then stratified based upon how many “defining” signs and symptoms that they had in addition to ILD and antibodies. Demographic characteristics, pulmonary function tests (PFT), chest CT’s—along with clinical outcomes were assessed.</div></div><div><h3>Results</h3><div>No differences in demographic factors and PFT’s were found between those who were diagnosed using Solomons versus Connors criteria. No differences in demographic, PFT’s and chest CT’s between those with ILD and antibodies only, with 1 additional criteria, and with 2+ additional criteria groups, although those with two or more additional criteria had a longer duration since diagnosis.</div></div><div><h3>Discussion</h3><div>Key findings from the study suggest that there are no differences in diagnostic outcomes, therapeutic interventions, or mortality rates when using different criteria to diagnose ASyS. This study suggests a reevaluation of diagnostic criteria for ASyS to prioritize ILD and relevant antibodies rather than a focus of additional criteria, supporting the new ASyS defining criteria from 273rd ENMC International Workshop (2024).</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101190"},"PeriodicalIF":2.2,"publicationDate":"2025-07-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144687363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Emerging respiratory challenges in space and long-duration missions","authors":"Benjamin Pequignot ,&nbsp;Seamus Thierry ,&nbsp;G Kim Prisk ,&nbsp;Mickael Lescroart","doi":"10.1016/j.resmer.2025.101188","DOIUrl":"10.1016/j.resmer.2025.101188","url":null,"abstract":"","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101188"},"PeriodicalIF":2.2,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144711500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of hemi-cannula in patients with high risk of recannulation in an intermediate respiratory care unit. A descriptive analysis and study of the predictor variables of the use of posterior non-invasive mechanical ventilation","authors":"Sergio Lopez-Ruz,&nbsp;Alba Fernández-Boza,&nbsp;Maria Andrea Jaimes-Castaño,&nbsp;Carlos Carrera-Cueva,&nbsp;Belen Muñoz-Sánchez,&nbsp;Emilio Garcia-Díaz,&nbsp;Demetrio González-Vergara,&nbsp;Javier Toral-Marin,&nbsp;Maria Barca-Hernando","doi":"10.1016/j.resmer.2025.101185","DOIUrl":"10.1016/j.resmer.2025.101185","url":null,"abstract":"<div><h3>Background</h3><div>Information about the decannulation process in patients with high risk of recannulation is limited. However, devices such as the hemi-cannula, which maintain airway permeability for a controlled period, may enhance the safety of this process.</div></div><div><h3>Aims</h3><div>Describe and analyze the variables in the decannulation process of patients with high risk of recannulation, who have used a hemi-cannula and correlate these variables with the posterior need for Non-Invasive Mechanical Ventilation (NIMV).</div></div><div><h3>Methods</h3><div>Unicentric study analyzing a retrospective cohort of consecutive patients admitted to the Intermediate Respiratory Care Unit (IRCU) to continue the decannulation process from April 2022 to April 2024. Sociodemographic and clinical variables were described and analyzed. SPSS software was used to analyze the data with T student for independent data and Chi-square with Fischer correction.</div></div><div><h3>Results</h3><div>The final cohort included 19 patients, whom most of them had no previous respiratory pathology, but a 47.4 % had some cardiovascular risk factors. All of the patients had polyneuropathy at the admission to the IRCU. No 30-day mortality was observed in any patient. The recannulation rate was 10.5 %. 21 % of the patients required subsequent NIMV. Statistical significance at the analysis of the correlation between the mean number of days of Invasive Mechanical Ventilation (IMV) and the need for subsequent NIMV was found. However, there was not with the remaining variables.</div></div><div><h3>Conclusions</h3><div>The use of devices such as the hemi-cannula can enhance safety during the complex decannulation process in patients with high risk of recannulation, reducing the likelihood of reintubation or readmission to the Intensive Care Unit (ICU).</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101185"},"PeriodicalIF":2.2,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144502145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Does occupational exposure affect the surgical management of patients with non-small cell lung cancer? A single-center retrospective experience","authors":"Matthieu Thumerel ,&nbsp;Camille Carles ,&nbsp;Hugues Begueret ,&nbsp;Quentin Thomas ,&nbsp;Jacques Jougon ,&nbsp;Carine Audoin ,&nbsp;Jean-François Bernaudin ,&nbsp;Patrick Brochard ,&nbsp;Yaniss Belaroussi","doi":"10.1016/j.resmer.2025.101183","DOIUrl":"10.1016/j.resmer.2025.101183","url":null,"abstract":"<div><h3>Objective</h3><div>Non-small-cell lung cancer (NSCLC) remains a major public health concern, with tobacco and environmental exposures to carcinogens (such as asbestos, radon, and silica) recognized as major risk factors. This study investigates the impact of occupational exposure, particularly to crystalline silica on peri‑ and postoperative outcomes in patients undergoing surgery for NSCLC.</div></div><div><h3>Methods</h3><div>A retrospective analysis was performed on 251 patients who underwent lobectomy or segmentectomy between 2018 and 2021, with occupational exposure data collected postoperatively.</div></div><div><h3>Results</h3><div>Our findings suggest that patients with occupational exposure, particularly to silica, asbestos, or multiple carcinogens, have more complex surgical courses, including longer operative times, higher rates of conversion from minimally invasive to open surgery, and increased postoperative complications (Clavien-Dindo grade II or higher). Preoperative lymph node staging was less accurate in exposed patients, in part because of inflammatory changes such as fibro-hyaline lesions, which can cause false-positive PET/CT findings.</div></div><div><h3>Conclusions</h3><div>The study highlights the need for tailored surgical strategies and accurate lymph node staging in exposed individuals. Future research should focus on prospective studies to refine perioperative management and explore the biological mechanisms driving these complications.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101183"},"PeriodicalIF":2.2,"publicationDate":"2025-06-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144510771","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Should segmentectomy indications be extended to NSCLC smaller than 3 cm without lymph node involvement? A retrospective single-center study","authors":"Damien Leveque ,&nbsp;Soufiane Lebal ,&nbsp;Tristan Goudou ,&nbsp;Mihaela Giol ,&nbsp;Denis Debrosse ,&nbsp;Marielle LE Roux ,&nbsp;Thérésa Khalife-Hocquemiller ,&nbsp;Anna Vayssette ,&nbsp;Juliette Camuset ,&nbsp;Alexandra Rousseau ,&nbsp;Jalal Assouad ,&nbsp;Harry Etienne","doi":"10.1016/j.resmer.2025.101179","DOIUrl":"10.1016/j.resmer.2025.101179","url":null,"abstract":"<div><h3>Introduction</h3><div>Surgical resection remains the standard treatment for stage IA non-small cell lung cancers (NSCLC). The dual objective of this study is to compare long-term outcomes of lobectomies and segmentectomies for stage IA NSCLC and to identify prognostic factors for resected stage IA NSCLC.</div></div><div><h3>Materials and Methods</h3><div>This is a retrospective monocentric study including patients diagnosed with NSCLC smaller than 3 cm, without lymph node involvement, from November 2015 to November 2021. The primary endpoint was event-free survival (EFS), defined as time from surgery to recurrence or all-cause death. Secondary endpoints included overall survival, recurrence-free survival, and short-term postoperative outcomes (length of stay, drainage duration, 30-day mortality, and postoperative complications). Prognostic factors were analyzed using multivariate Cox regression adjusted for variables identified in univariate analysis.</div></div><div><h3>Results</h3><div>A total of 457 patients underwent surgery for stage cIA NSCLC during the 11study period. Of these, 176 (38.5 %) had a segmentectomy, and 281 (61.5 %) underwent lobectomy. Among patients with cT1N0 tumors, the 5-year event-free survival did not significantly differ between the segmentectomy and lobectomy groups (adjusted HR = 0.59 (0.32; 1.08), <em>p</em> = 0.086), with 5-year event-free rates of 75.0 % and 83.0 %, respectively (<em>p</em> = 0.054). Multivariate analysis revealed an association between nodule type (solid vs. ground-glass or mixed) and event-free survival (death and/or recurrence) ([adjusted HR =2.07 (1.17–3.66), <em>p</em> = 0.01)]. Vascular and/or lymphatic invasion is associated with a decrease in event-free survival (recurrence or death) [adjusted HR = 2.25 (1.29; 3.92), <em>p</em> = 0.004]. Conversion from segmentectomy to lobectomy occurred in 6 patients (3.4 %), and they were included in the lobectomy group for analysis.</div></div><div><h3>Conclusion</h3><div>For patients with clinical stage cIA NSCLC, segmentectomy appears to offer comparable oncologic outcomes to lobectomy. Tumor characteristics, including radiological appearance and histological factors, should be carefully considered when selecting the appropriate surgical strategy. Prospective multicenter studies are needed to confirm these findings.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101179"},"PeriodicalIF":2.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144580404","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early mobilization and functional outcomes in cystic fibrosis patients after lung transplantation: A single-center retrospective study","authors":"Matthieu Reffienna ,&nbsp;Jeremy Roussel ,&nbsp;Gabor Kalman ,&nbsp;Mathilde Labro ,&nbsp;Charles Cerf ,&nbsp;François Parquin","doi":"10.1016/j.resmer.2025.101184","DOIUrl":"10.1016/j.resmer.2025.101184","url":null,"abstract":"<div><h3>Background</h3><div>Rehabilitation has been shown to enhance patient performance before and after lung transplantation, but limited data exist on its role during the immediate post-transplant phase in critical care units.</div></div><div><h3>Methods</h3><div>We conducted a single-center retrospective study. All adult patients who underwent bilateral transplantation for cystic fibrosis were included. Patients were followed from admission to discharge from critical care. All rehabilitation sessions were recorded. We aimed to evaluate the relationship between the amount of mobilization performed by the patient in critical care, and functional performance at discharge.</div></div><div><h3>Results</h3><div>We included 36 patients (21 males) with a median age of 29 years (IQR: 24.5–35.0) and a median critical care length of stay of 15 days (12.5–20). Patients performed a total of 388 sessions of rehabilitation. Out-of-bed mobilization started at a median of post-operative day 2.5 (IQR: 1.0–4.5), with the first walking session at day 3 (IQR: 2.0–4.5). A strong correlation was found between daily walking distance and functional performance, as measured by the 6-minute walk test, with a Pearson correlation coefficient of 0.70 (95 % CI: 0.48–0.84).</div></div><div><h3>Conclusions</h3><div>After lung transplantation for cystic fibrosis, early initiated rehabilitation in critical care is feasible and can improve patients' functional performance. These findings are promising, but require validation in other lung transplant populations.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101184"},"PeriodicalIF":2.2,"publicationDate":"2025-05-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314012","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Endobronchial valve (EBV) insertion for severe emphysema does not improve skeletal muscle mass or function: A pilot study on 19 patients","authors":"Julia Rubenstein ,&nbsp;Ilyès Benlala ,&nbsp;Emilie Mesa ,&nbsp;Anne-Claire Toublanc ,&nbsp;Marina Gueçamburu ,&nbsp;Arnaud Maurac ,&nbsp;Claire Bon ,&nbsp;Charlotte Vergnenegre ,&nbsp;Léo Grassion ,&nbsp;Geoffroy Moucheboeuf ,&nbsp;Patrick Dehail ,&nbsp;Gaël Dournes ,&nbsp;Maéva Zysman ,&nbsp;Pauline Henrot","doi":"10.1016/j.resmer.2025.101178","DOIUrl":"10.1016/j.resmer.2025.101178","url":null,"abstract":"<div><div>Endobronchial valve (EBV) insertion for severe emphysema allows to reduce hyperinflation and alleviates respiratory symptoms in patients with chronic obstructive pulmonary disease (COPD). However, few studies investigate its effect on extra-pulmonary manifestations. We sought to assess the effect of EBV insertion on skeletal muscle mass and function, as well as determine if skeletal muscle parameters could represent a prognostic factor for response to EBV insertion.</div><div>We conducted a monocentric prospective pilot study including 19 patients. Exhaustive evaluation of lung &amp; skeletal muscle parameters was performed at baseline and 3 and 6 months after EBV insertion. Our primary aim was to assess the 6-month change in skeletal muscle parameters i.e. assessment of body composition with bioimpedance analysis (appendicular skeletal muscle mass index, fat mass, phase angle), evaluation of thoracic muscles (pectoralis, erector spinal, 5th intercostalis, psoas) surfaces and densities on CT-scans, and of upper limb force with handgrip test.</div><div>EBV insertion led to a significant improvement of lung function after 3 months and persisting at 6 months. In contrast, no significant improvement was observed in skeletal muscle parameters. In addition, no muscle parameter nor sarcopenic status was found to predict response to EBV insertion.</div><div>These results suggest that EBV insertion is not associated with strong systemic effects in our study, as well as emphasize the need to find bottom-up drug strategies for COPD-associated sarcopenia.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101178"},"PeriodicalIF":2.2,"publicationDate":"2025-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490149","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Acute effects of fan therapy on exercise-induced breathlessness in healthy adults and people living with chronic respiratory disease: A systematic review","authors":"Julien Da Purificaçao ,&nbsp;Clémence Pierret ,&nbsp;Tristan Bonnevie ,&nbsp;William Poncin","doi":"10.1016/j.resmer.2025.101172","DOIUrl":"10.1016/j.resmer.2025.101172","url":null,"abstract":"<div><h3>Background</h3><div>Exercise-induced breathlessness is a common complaint in the general population and a highly prevalent symptom in adults living with chronic diseases, often acting as an important barrier to engaging in physical activity. Fan therapy can reduce breathlessness at rest, yet its acute effects during exercise have not been systematically explored.</div></div><div><h3>Methods</h3><div>A literature search encompassing three electronic databases (PubMed, Scopus, Embase) from inception to January 2025 was conducted to identify randomized controlled trials comparing fan therapy during and after an acute exercise bout to a control condition, on dyspnea and exercise capacity. Relevant conference abstracts were considered. Risk of bias was assessed via the Physiotherapy Evidence Database scale. The PRISMA guidelines were followed.</div></div><div><h3>Results</h3><div>A total of six studies, including one conference abstract, met eligibility criteria. Five records involved 79 adults with chronic respiratory disease, all presenting a respiratory disease, and the remaining record included 10 healthy individuals. The results were generally consistent, showing that fan therapy significantly reduces exercise-induced breathlessness (<em>n</em> = 2 studies), decreases breathlessness during recovery (<em>n</em> = 5), and enhances exercise capacity (<em>n</em> = 2). The methodological quality was good for half or retrieved studies and poor-to-fair in the other half.</div></div><div><h3>Conclusion</h3><div>Fan therapy might relieve dyspnea and improve exercise capacity during and after an acute bout of exercise in patients with chronic respiratory disease. Future high-quality research should confirm these findings and consider assessing fan therapy effects in other populations. PROSPERO number: CRD42023475117</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101172"},"PeriodicalIF":2.2,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143947998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-Mi-2 positive interstitial lung disease (ILD): A progressive disease comparable to other myositis-ILD","authors":"Bess M. Flashner ,&nbsp;Ryosuke Imai ,&nbsp;Andrew J. Synn ,&nbsp;Julia K. Munchel ,&nbsp;Lida P. Hariri ,&nbsp;Fiona K. Gibbons ,&nbsp;Sydney B. Montesi ,&nbsp;Barry S. Shea ,&nbsp;Mary B. Rice ,&nbsp;Rene S. Bermea ,&nbsp;Robert W. Hallowell","doi":"10.1016/j.resmer.2025.101176","DOIUrl":"10.1016/j.resmer.2025.101176","url":null,"abstract":"<div><h3>Background</h3><div>Evaluation for interstitial lung disease (ILD) often involves sending a myositis panel that includes myositis-associated and myositis-specific antibodies (MAA and MSA respectively) such as anti-Mi-2. Little is known about anti-Mi-2 positive ILD. We sought to determine the typical presentation and prognosis of anti-Mi-2 positive ILD.</div></div><div><h3>Methods</h3><div>We performed a retrospective chart review of patients in two ILD referral centers in Boston, MA with a positive anti-Mi-2 antibody between 2012 and 2024. Patients were identified by query of the medical record for patients with anti-Mi-2, and we included those with ILD on chest computed tomography (CT). We conducted survival analyses for ILD progression-free and overall survival using Kaplan-Meier curves and log-rank tests. Additionally, a Cox proportional-hazards model was employed, adjusting for age, gender, baseline forced vital capacity, and immunosuppressant use to calculate hazard ratios. The comparator group included patients who were followed longitudinally in the ILD clinic who were anti-Mi-2 negative but positive for other MSAs.</div></div><div><h3>Results</h3><div>Fifty-eight patients were identified. Half (52 %) were female with mean age 67 years (SD 13 years). The majority had dyspnea and/or cough, and a quarter of patients required oxygen upon presentation. Six (10 %) had PM/DM that pre-dated their ILD diagnosis. Other autoantibody positivity was common; one-third-of patients (<em>n</em> = 19, 33 %) were positive for anti-Mi-2 alone without positivity for other MSAs or MAAs. Clinical follow up data were available for 52 patients for a median follow up of 24 months (range &lt;1 month-10 years). PFT progression was seen in 67 % and radiologic progression was seen in over a third. Half received immunosuppression (55 %), with 19 % requiring multiple immunosuppressives. During follow up, 21 % had acute exacerbation of ILD or death. Progression-free and overall survival were not significantly different among anti-Mi-2 positive ILD <em>versus</em> anti-Mi-2 negative, MSA positive ILD patients regardless of anti-Mi-2 positivity alone or in combination with other autoantibodies.</div></div><div><h3>Conclusions</h3><div>This series of 58 patients is the largest anti-Mi-2 positive ILD cohort to date. Concurrent positivity with other autoantibodies associated with ILD was common. Anti-Mi-2 positive ILD was associated with similar outcomes to those with other MSAs. Larger studies are needed to better characterize patients with Mi-2 positive ILD.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101176"},"PeriodicalIF":2.2,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144177511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Outcomes of cannabis smoking in patients with lung cancer: findings from KBP-CPHG-2020","authors":"Sébastien Couraud ,&nbsp;Olivier Molinier ,&nbsp;Marielle Sabatini ,&nbsp;Séverine Thomassin ,&nbsp;Rym Haouachi ,&nbsp;Virginie Levrat ,&nbsp;Hannah Ghalloussi-Tebai ,&nbsp;Antoine Belle ,&nbsp;Laurent Mosser ,&nbsp;Sébastien Larive ,&nbsp;Alexandra Bedossa ,&nbsp;Alexia Letierce ,&nbsp;Hugues Morel ,&nbsp;Didier Debieuvre ,&nbsp;Study Group KBP-2020-CPHG","doi":"10.1016/j.resmer.2025.101174","DOIUrl":"10.1016/j.resmer.2025.101174","url":null,"abstract":"<div><h3>Introduction</h3><div>Cannabis smoking is suspected to be a risk factor for lung cancer. The KBP-2020-CPHG study is a prospective study that collected data from all patients with newly diagnosed lung cancer in non-academic hospitals in France in 2020.</div></div><div><h3>Method</h3><div>We conducted comparative and matched cohort analyses using the dataset, in which cannabis smokers (i.e. participants who self-declared a lifetime intake of ≥20 joints) were compared with tobacco-only smokers. After matching on confounders, we compared age at diagnosis and overall survival.</div></div><div><h3>Results</h3><div>Among 8999 patients, 314 (3.6%) were cannabis smokers and 7372 were tobacco-only smokers (data missing for 183). Cannabis smokers were younger than tobacco-only smokers at lung cancer diagnosis (mean [± standard deviation] 52.9 [±8.84] <em>versus</em> 67.7 [±9.51] years; p&lt;0.0001), and this difference remained in the paired analysis (matched for histology, sex and cigarette pack-years [±5 pack-years]; n = 298 pairs; median age at diagnosis 53.1 <em>vs</em> 64.8 years; hazard ratio 5.61, 95% CI 4.10–7.68; p&lt;0.0001). Histological type was also different between the two groups, with more cases of adenocarcinoma and large cell neuroendocrine carcinoma among cannabis smokers. Finally, a 1:1 matched analysis controlled for age, sex, stage, histology and cigarette pack-years showed that overall survival was not affected by cannabis smoking (HR 0.90, 95% CI 0.68–1.18; p = 0.44).</div></div><div><h3>Conclusion</h3><div>We provide a detailed description of lung cancer characteristics among cannabis smokers compared with tobacco-only smokers. Cannabis smoking appeared to be associated with lung cancer diagnosis at an earlier age and was not a prognostic factor for mortality.</div></div>","PeriodicalId":48479,"journal":{"name":"Respiratory Medicine and Research","volume":"88 ","pages":"Article 101174"},"PeriodicalIF":2.2,"publicationDate":"2025-05-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144090101","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}